If all American voters were single-issue deciders and the cost of healthcare were their issue, Democrat candidates would win the mid-term elections handily. But loyalists of the donkey party shouldn’t be smug around their elephant counterparts. 

A past president of the RSNA and Rutgers RO chair, Bruce Haffty, MD, will serve as the college's new chief medical officer for radiation oncology research.

How politically heated is the present moment? Enough to elicit verbal violence from trusted nurses. 

The American Board of Cardiovascular Medicine is still pushing forward with its efforts to change how cardiologists are certified in the United States. While the group can reapply in the future for a standalone cardiology board, it is also looking at possible partnerships with other organizations.

Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.

Executives from two of the world’s largest medtech companies, Medtronic and Boston Scientific, are among the leaders calling for "state, local and federal officials to work together to find real solutions."

Julie Szeker, the publicly traded company’s chief legal officer and corporate secretary, submitted her resignation on Jan. 12, according to an SEC filing.

CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.